Author: krishkhubchand

There’s a stark reality haunting the halls of enterprise IT departments right now: implementing AI isn’t just a technical challenge, it’s a double-headed monster of supply chain and accuracy problems. Want to deploy a language model? First, get in line behind Meta, Google, and Microsoft for those precious GPUs. Oh, and while you’re waiting (about 12-18 months at current estimates), maybe take out a second mortgage to afford them. Then comes the fun part: hoping your general-purpose AI model is actually accurate enough for your specific business needs. Enter Fastino, emerging from stealth today with a compelling proposition: what if…

The $4M bet on making drug marketing less painful than the diseases it advertises Here’s a fun game: Take a pharmaceutical TV ad, change three words, and accidentally imply your drug causes spontaneous combustion. Congratulations! You’ve just cost your company millions in regulatory fines and a painful FDA letter that will hang in your office like a reverse diploma. This, in essence, is why pharmaceutical companies have entire departments dedicated to making sure their marketing materials don’t accidentally promise eternal life or forget to mention that one tiny side effect about growing a third arm. It’s called the Medical, Legal,…

The Brief: The Insight: The Series B round highlights strong investor confidence in 11x.ai amid increasing competition in AI SDR solutions, where differentiation is a challenge. Despite some investor caution in the space, 11x.ai’s significant funding demonstrates belief in its growth potential. Competitive Landscape: Product Snapshot: The Big Picture: As more companies turn to AI to streamline and scale sales operations, AI SDRs are becoming pivotal. For 11x.ai, maintaining ARR growth and unique product capabilities will be essential to standing out and sustaining investor interest as the market continues to expand. What’s Next: With fresh capital from Andreessen Horowitz, 11x.ai…